# OnCo record nct06772623 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06772623/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06772623", "NCT06772623" ;
  schema:name "Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations"@en ;
  schema:description "A phase 1/2 trial of Telisotuzumab adizutecan, Budigalimab, Pembrolizumab, Carboplatin, Pemetrexed and Cisplatin in non-small-cell lung cancer, run by AbbVie, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06772623/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06772623> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2025-03-06" ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:drugs <https://onco.cc/drugs/telisotuzumab-adizutecan/>, <https://onco.cc/drugs/budigalimab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/pemetrexed/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/abbvie/> .